These anti-inflammatory effects of the PDE4 inhibitor may translate into the improved lung function and reduced rate of exacerbations in patients with moderate to severe COPD as recently documented in large-scale clinical trials. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.